SEC Form 4 · accession 0000899243-18-003750
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lesley Ann Calhoun
Officer — See Remarks
Period of report
Feb 1, 2018
Accepted (ET)
Feb 13, 2018 · 9:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $59.60 | Feb 1, 2018 | A | 9,000 | A | — | Jan 31, 2028 | Common Stock | 9,000 | 9,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 1, 2018 | A | 6,000 | A | — | — | Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1The Stock Option becomes exercisable in sixteen equal quarterly installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- F2Each restricted stock unit represents a contingent right to receive one share of GBT common stock.
- F3The Restricted Stock Units vest in eight semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Vice President, Finance and Principal Accounting Officer